{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:08:52Z","timestamp":1789884532563,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,9,10]],"date-time":"2014-09-10T00:00:00Z","timestamp":1410307200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/s12955-014-0140-1","type":"journal-article","created":{"date-parts":[[2014,9,9]],"date-time":"2014-09-09T14:15:53Z","timestamp":1410272153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death"],"prefix":"10.1186","volume":"12","author":[{"given":"Anthony J","family":"Hatswell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Pericleous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Rowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Lebmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,10]]},"reference":[{"key":"140_CR1","first-page":"661","volume":"29","author":"F Salaffi","year":"2011","unstructured":"Salaffi F, Carotti M, Ciapetti A, Gasparini S, Grassi W: A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011, 29: 661\u2013671.","journal-title":"Clin Exp Rheumatol"},{"key":"140_CR2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jval.2011.09.010","volume":"15","author":"J S\u00d8rensen","year":"2012","unstructured":"S\u00d8rensen J, Linde L, \u00d8stergaard M, Hetland ML: Quality-adjusted life expectancies in patients with rheumatoid arthritis - comparison of index scores from EQ-5D, 15D, and SF-6D. Value Health 2012, 15: 334\u2013339. 10.1016\/j.jval.2011.09.010","journal-title":"Value Health"},{"key":"140_CR3","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2165\/11588360-000000000-00000","volume":"29","author":"M Parker","year":"2011","unstructured":"Parker M, Haycox A, Graves J: Estimating the relationship between preference-based generic utility instruments and disease-specific quality-of-life measures in severe chronic constipation: challenges in practice. Pharmacoeconomics 2011, 29: 719\u2013730. 10.2165\/11588360-000000000-00000","journal-title":"Pharmacoeconomics"},{"key":"140_CR4","unstructured":"Cancer Research UK: Melanoma risks and causes. , [ http:\/\/www.cancerhelp.org.uk\/type\/melanoma\/about\/melanoma-risks-and-causes ]"},{"key":"140_CR5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebb\u00e9 C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363: 711\u2013723. 10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"key":"140_CR6","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jval.2011.01.004","volume":"14","author":"D Rowen","year":"2011","unstructured":"Rowen D, Brazier J, Young T, Gaugris S, Craig BM, King MT, Velikova G: Deriving a preference-based measure for cancer using the EORTC QLQ-C30. Value Health 2011, 14: 721\u2013731. 10.1016\/j.jval.2011.01.004","journal-title":"Value Health"},{"key":"140_CR7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","volume":"21","author":"J Brazier","year":"2002","unstructured":"Brazier J, Roberts J, Deverill M: The estimation a preference-based single index measure for health from the SF-36. J Health Econ 2002, 21: 271\u2013292. 10.1016\/S0167-6296(01)00130-8","journal-title":"J Health Econ"},{"key":"140_CR8","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/hec.866","volume":"13","author":"J Brazier","year":"2004","unstructured":"Brazier J, Roberts J, Tsuchiya A, Busschbach J: A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004, 13: 873\u2013884. 10.1002\/hec.866","journal-title":"Health Econ"},{"key":"140_CR9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jhealeco.2006.09.002","volume":"26","author":"SA Kharroubi","year":"2007","unstructured":"Kharroubi SA, Brazier JE, Roberts J, O'Hagan A: Modelling SF-6D health state preference data using a nonparametric Bayesian method. J Health Econ 2007, 26: 597\u2013612. 10.1016\/j.jhealeco.2006.09.002","journal-title":"J Health Econ"},{"key":"140_CR10","unstructured":"Kind P, Hardman G, Macran S: UK population norms for EQ-5D. Discussion paper 172. , [ http:\/\/www.york.ac.uk\/media\/che\/documents\/papers\/discussionpapers\/CHE%20Discussion%20Paper%20172.pdf ]"},{"key":"140_CR11","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/0272989X10380924","volume":"31","author":"CM McDonough","year":"2011","unstructured":"McDonough CM, Tosteson TD, Tosteson AN, Jette AM, Grove MR, Weinstein JN: A longitudinal comparison of 6 preference-weighted health state classification systems in persons with intervertebral disk herniation. Med Decis Making 2011, 31: 270\u2013280. 10.1177\/0272989X10380924","journal-title":"Med Decis Making"},{"key":"140_CR12","unstructured":"National Institute for Health and Clinical Excellence (NICE): Guide to the methods of technology appraisal. , [ http:\/\/www.nice.org.uk\/media\/B52\/A7\/TAMethodsGuideUpdatedJune2008.pdf ]"},{"key":"140_CR13","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jval.2012.08.2201","volume":"15","author":"D Rowen","year":"2012","unstructured":"Rowen D, Young T, Brazier J, Gaugris S: Comparison of Generic, Condition-Specific, and Mapped Health State Utility Values for Multiple Myeloma Cancer. Value Health 2012, 15: 1059\u20131068. 10.1016\/j.jval.2012.08.2201","journal-title":"Value Health"},{"key":"140_CR14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40273-014-0136-z","volume":"32","author":"T Wisl\u00d8ff","year":"2014","unstructured":"Wisl\u00d8ff T, Hagen G, Hamidi V, Movik E, Klemp M, Estimating OJA: Gains in Applied Studies: A Review of Cost-Utility Analyses Published in 2010. Pharmacoeconomics 2014, 32: 367\u2013375. 10.1007\/s40273-014-0136-z","journal-title":"Pharmacoeconomics"},{"key":"140_CR15","doi-asserted-by":"crossref","unstructured":"Brazier J, Rowen D, Mavranezouli I, Tsuchiya A, Young T, Yang Y, Barkham M, Ibbotson R: Developing and testing methods for deriving preference-based measures of health from condition specific measures (and other patient based measures of outcome). , [ http:\/\/www.hta.ac.uk\/1744 ]","DOI":"10.3310\/hta16320"},{"issue":"7","key":"140_CR16","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/annonc\/mdu154","volume":"25","author":"J-J Grob","year":"2014","unstructured":"Grob J-J, Amonkar MM, Martin-Algarra S, Demidov LV, Goodman V, Grotzinger K, Haney P, K\u00e4mpgen E, Karaszewska B, Mauch C, Miller WH Jr, Millward M, Mirakhur B, Rutkowski P, Chiarion-Sileni V, Swann A, Hauschild A: Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. Ann Oncol 2014, 25(7):1428\u20131436. 10.1093\/annonc\/mdu154","journal-title":"Ann Oncol"},{"issue":"6","key":"140_CR17","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jval.2011.04.003","volume":"14","author":"RL Askew","year":"2011","unstructured":"Askew RL, Swartz RJ, Xing Y, Cantor SB, Ross MI, Gershenwald JE, Palmer JL, Lee JE, Cormier JN: Mapping FACT-melanoma quality-of-life scores to EQ-5D health utility weights. Value Health 2011, 14(6):900\u2013906. 10.1016\/j.jval.2011.04.003","journal-title":"Value Health"},{"issue":"4","key":"140_CR18","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.bjc.6602973","volume":"94","author":"S Dixon","year":"2006","unstructured":"Dixon S, Walters SJ, Turner L, Hancock BW: Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial. Br J Cancer 2006, 94(4):492\u2013498. 10.1038\/sj.bjc.6602973","journal-title":"Br J Cancer"},{"key":"140_CR19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bjc.6605187","volume":"101","author":"KM Beusterien","year":"2009","unstructured":"Beusterien KM, Szabo SM, Kotapati S, Mukherjee J, Hoos A, Hersey P, Middleton MR, Levy AR: Societal preference values for advanced melanoma health states in the United Kingdom and Australia. Br J Cancer 2009, 101: 387\u2013389. 10.1038\/sj.bjc.6605187","journal-title":"Br J Cancer"},{"key":"140_CR20","volume-title":"Standard gamble utilities for advanced melanoma health states elicited from the Canadian general public [Abstract]. Presented at the 7th International Melanoma Congress","author":"D Hogg","year":"2010","unstructured":"Hogg D, Osenenko K, Szabo SM, Schultz M, Donato BM, Lane S, Levy AR: Standard gamble utilities for advanced melanoma health states elicited from the Canadian general public [Abstract]. Presented at the 7th International Melanoma Congress. John Wiley, Sydney, Australia; 2010."},{"key":"140_CR21","doi-asserted-by":"crossref","unstructured":"Tolley K, Goad C, Yi Y, Maroudas P, Haiderali A, Thompson G: Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia. Eur J Health Econ 2012, Sep 1. [Epub ahead of print].","DOI":"10.1007\/s10198-012-0419-2"},{"key":"140_CR22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1477-7525-6-105","volume":"6","author":"A Briggs","year":"2008","unstructured":"Briggs A, Wild D, Lees M, Reaney M, Dursun S, Parry D, Mukherjee J: Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes 2008, 6: 105. 10.1186\/1477-7525-6-105","journal-title":"Health Qual Life Outcomes"},{"key":"140_CR23","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","volume":"95","author":"A Lloyd","year":"2006","unstructured":"Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J: Health state utilities for metastatic breast cancer. Br J Cancer 2006, 95: 683\u2013690. 10.1038\/sj.bjc.6603326","journal-title":"Br J Cancer"},{"key":"140_CR24","unstructured":"Brazier JE, Rowen D: NICE DSU Technical Support Document 11: Alternatives to EQ-5D for generating health state utility values. , [ http:\/\/www.nicedsu.org.uk\/TSD11%20Alternatives%20to%20EQ-5D_final.pdf ]"},{"issue":"5","key":"140_CR25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00019053-200725050-00002","volume":"25","author":"AS Pickard","year":"2007","unstructured":"Pickard AS, Wilke CT, Lin HW, Lloyd A: Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics 2007, 25(5):365\u2013384. 10.2165\/00019053-200725050-00002","journal-title":"Pharmacoeconomics"},{"key":"140_CR26","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1200\/JCO.2007.13.3439","volume":"26","author":"CC Gotay","year":"2008","unstructured":"Gotay CC, Kawamoto CT, Bottomley A, Efficace F: The Prognostic Significance of Patient-Reported Outcomes in Cancer Clinical Trials. J Clin Oncol 2008, 26: 1355\u20131363. 10.1200\/JCO.2007.13.3439","journal-title":"J Clin Oncol"},{"key":"140_CR27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1477-7525-7-102","volume":"7","author":"A Montazeri","year":"2009","unstructured":"Montazeri A: Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes 2009, 7: 102. 10.1186\/1477-7525-7-102","journal-title":"Health Qual Life Outcomes"},{"key":"140_CR28","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebb\u00e9 C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS: Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 2009, 15: 7412\u20137420. 10.1158\/1078-0432.CCR-09-1624","journal-title":"Clin Cancer Res"},{"key":"140_CR29","unstructured":"Scottish Medicines Consortium: Guidance to Manufacturers. Guidance for completion of New Product Assessment Form for Full Submissions. , [ http:\/\/www.scottishmedicines.org.uk\/Submission_Process\/Submission_Guidance_and_Templates_for_Industry\/Templates-Guidance-for-Submission\/Templates-Guidance-for-Submission ]"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-014-0140-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12955-014-0140-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-014-0140-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T20:28:39Z","timestamp":1565814519000},"score":1,"resource":{"primary":{"URL":"http:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/s12955-014-0140-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,10]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["140"],"URL":"https:\/\/doi.org\/10.1186\/s12955-014-0140-1","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,10]]},"article-number":"140"}}